HUE058661T2 - Morfolinilpiridon vegyületek - Google Patents

Morfolinilpiridon vegyületek

Info

Publication number
HUE058661T2
HUE058661T2 HUE18759105A HUE18759105A HUE058661T2 HU E058661 T2 HUE058661 T2 HU E058661T2 HU E18759105 A HUE18759105 A HU E18759105A HU E18759105 A HUE18759105 A HU E18759105A HU E058661 T2 HUE058661 T2 HU E058661T2
Authority
HU
Hungary
Prior art keywords
morpholinylpyridone
compounds
morpholinylpyridone compounds
Prior art date
Application number
HUE18759105A
Other languages
English (en)
Hungarian (hu)
Inventor
Johan Lindstroem
Rickard Forsblom
Jenny Viklund
Original Assignee
Sprint Bioscience Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sprint Bioscience Ab filed Critical Sprint Bioscience Ab
Publication of HUE058661T2 publication Critical patent/HUE058661T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUE18759105A 2017-08-23 2018-08-23 Morfolinilpiridon vegyületek HUE058661T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17187567 2017-08-23

Publications (1)

Publication Number Publication Date
HUE058661T2 true HUE058661T2 (hu) 2022-09-28

Family

ID=59686888

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE18759105A HUE058661T2 (hu) 2017-08-23 2018-08-23 Morfolinilpiridon vegyületek

Country Status (20)

Country Link
US (2) US11560374B2 (OSRAM)
EP (2) EP4056569A1 (OSRAM)
JP (2) JP7199736B2 (OSRAM)
KR (1) KR102732013B1 (OSRAM)
CN (3) CN111108102B (OSRAM)
AU (2) AU2018320419B2 (OSRAM)
CY (1) CY1125117T1 (OSRAM)
DK (1) DK3672962T3 (OSRAM)
ES (1) ES2910157T3 (OSRAM)
HR (1) HRP20220497T1 (OSRAM)
HU (1) HUE058661T2 (OSRAM)
IL (3) IL302077A (OSRAM)
LT (1) LT3672962T (OSRAM)
PL (1) PL3672962T3 (OSRAM)
PT (1) PT3672962T (OSRAM)
RS (1) RS63109B1 (OSRAM)
SI (1) SI3672962T1 (OSRAM)
SM (1) SMT202200169T1 (OSRAM)
TW (2) TW202348601A (OSRAM)
WO (1) WO2019038390A1 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023550641A (ja) * 2020-11-25 2023-12-04 デシフェラ・ファーマシューティカルズ,エルエルシー ウイルス感染症の治療に使用するためのvsp34阻害剤としてのモルホリノ誘導体
CN117241800A (zh) * 2020-11-25 2023-12-15 德西费拉制药有限责任公司 Vps34抑制剂的抗病毒活性
WO2022115562A1 (en) 2020-11-25 2022-06-02 Deciphera Pharmaceuticals, Llc Morpholino derivatives as vsp34 inhibitors for use in the treatment of a viral infection

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7622486B2 (en) * 2004-09-23 2009-11-24 Reddy Us Therapeutics, Inc. Pyridine compounds, process for their preparation and compositions containing them
WO2011058478A1 (en) * 2009-11-16 2011-05-19 Pfizer Inc. Substituted triazolopyrimidines as pde8 inhibitors
MX2013007336A (es) 2010-12-21 2013-08-01 Novartis Ag Compuestos de bi-heteroarilo como inhibidores de vps34.
WO2012085244A1 (fr) * 2010-12-23 2012-06-28 Sanofi Derives de pyrimidinone, leur preparation et leur utilisation pharmaceutique
FR2969612B1 (fr) * 2010-12-23 2013-02-08 Sanofi Aventis Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique
GB201120317D0 (en) 2011-11-24 2012-01-04 Queen Mary & Westfield College Screening method
FR2992314B1 (fr) 2012-06-22 2015-10-16 Sanofi Sa Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique
WO2015030057A1 (ja) * 2013-08-29 2015-03-05 富士フイルム株式会社 新規なモルホリン誘導体またはその塩
CN105916503B (zh) 2014-01-14 2020-04-14 米伦纽姆医药公司 杂芳基化合物和其用途
JP2017502092A (ja) 2014-01-14 2017-01-19 ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. ヘテロアリール及びその使用
MA39823A (fr) 2014-04-03 2018-01-09 Janssen Pharmaceutica Nv Dérivés de pyridine macrocyclique
MA39822A (fr) 2014-04-03 2018-02-06 Janssen Pharmaceutica Nv Dérivés de pyrimidine bicycle
WO2017009751A1 (en) 2015-07-15 2017-01-19 Pfizer Inc. Pyrimidine derivatives
CN108884067B (zh) * 2016-02-19 2021-01-08 思普瑞特生物科学公司 可用于治疗癌症和糖尿病的6-杂环基-4-吗啉-4-基吡啶-2-酮化合物
PT3416945T (pt) * 2016-02-19 2020-09-11 Sprint Bioscience Ab Compostos de 6-aril-4-(morfolin-4-il)-1h-piridina-2-ona úteis para o tratamento do cancro e da diabetes

Also Published As

Publication number Publication date
EP3672962A1 (en) 2020-07-01
ES2910157T3 (es) 2022-05-11
LT3672962T (lt) 2022-05-10
HRP20220497T1 (hr) 2022-05-27
AU2018320419A1 (en) 2020-04-09
US20200361922A1 (en) 2020-11-19
CA3073142A1 (en) 2019-02-28
IL272815B (en) 2022-06-01
DK3672962T3 (da) 2022-05-02
WO2019038390A1 (en) 2019-02-28
KR102732013B1 (ko) 2024-11-18
CY1125117T1 (el) 2024-12-13
EP4056569A1 (en) 2022-09-14
IL302077A (en) 2023-06-01
SI3672962T1 (sl) 2022-06-30
CN111108102B (zh) 2023-04-28
IL272815A (en) 2020-04-30
US20230234949A1 (en) 2023-07-27
EP3672962B1 (en) 2022-01-26
JP2020531485A (ja) 2020-11-05
CN116462674A (zh) 2023-07-21
JP7199736B2 (ja) 2023-01-06
IL292489B2 (en) 2023-09-01
RS63109B1 (sr) 2022-04-29
AU2018320419B2 (en) 2023-09-28
TWI803511B (zh) 2023-06-01
AU2023285995A1 (en) 2024-01-25
IL292489B1 (en) 2023-05-01
JP2023021268A (ja) 2023-02-10
CN111108102A (zh) 2020-05-05
TW201912161A (zh) 2019-04-01
PT3672962T (pt) 2022-04-12
US11560374B2 (en) 2023-01-24
RU2020110506A (ru) 2021-09-23
IL292489A (en) 2022-06-01
KR20200044025A (ko) 2020-04-28
RU2020110506A3 (OSRAM) 2022-02-22
PL3672962T3 (pl) 2022-05-02
CN116444510A (zh) 2023-07-18
SMT202200169T1 (it) 2022-05-12
TW202348601A (zh) 2023-12-16

Similar Documents

Publication Publication Date Title
DK3731771T3 (da) V462033dk00
EP3578560A4 (en) QUINAZOLINE COMPOUND
EP3609871A4 (en) ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS
CL2018000524S1 (es) Golilla
DE202018003363U8 (de) Handgelenkssphygmomanometer
EP3634404C0 (en) PYRAZOLE-BASED MAGL INHIBITORS
EP3589248A4 (en) CRYOTHERAPIES
EP3588580A4 (en) SCHOTTKY MOS TRENCH DIODE
DK3351526T3 (da) Diisopentylterephthalat
DK4039675T3 (da) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl forbindelser
EP3634397A4 (en) HETEROCYCLYL POLYMETHINE-BASED IR CHROMOPHORES
DK3568655T3 (da) Rekuperator
DK3571580T3 (da) Load-logical-and-shift-guarded-instruktion
LT3464336T (lt) Junginiai
DK3612237T3 (da) Genterapi
EP3575467A4 (en) NON-WOVEN FABRIC THREADED
EP3611402A4 (en) SERVO CYLINDER
DK3576686T3 (da) Brokbind
DK3568506T3 (da) Offeranode
DK3672941T3 (da) Pyridylpyridonforbindelser
EP3569893A4 (en) CHAIN TENSIONER
DK3672962T3 (da) Morpholinylpyridonforbindelser
LT3668879T (lt) Nauji junginiai
DK3510051T3 (da) Carboxylalkylchitosan
DK3676276T3 (da) Spirothietannukleosider